Please login to the form below

Not currently logged in
Email:
Password:

W2O bolsters its commercialisation offering

Rita Glaze joins the firm as leader of value, pricing and market access practice

Rita GlazeW2O, an independent network of analytics, marketing and communications firms, has appointed Rita Glaze as its new practice leader of value, pricing and market access.

The new role aims to strengthen the group’s healthcare commercialisation offering and together with the practice’s founder Brian Reid, Glaze will build a multi-dimensional team to help clients with pricing and reimbursement strategy and communications.

She said: “I am thrilled to have joined W2O and look forward to working with Brian and the team to build this practice.

“We have the opportunity, through an analytics-driven approach, to work closely with pharmaceutical and biotech companies to align commercial objectives with the pricing and value realities within their markets.”

Glaze has 25 years’ experience in the biopharmaceutical and life science sector with expertise in marketing, managed markets, pricing strategy and communications.

She has held senior positions with organisations such as Takeda, Allscripts, Searle/Pharmacia.

Joining the network from Edelman, Glaze previously led the design and implementation of its US market access communications offering.

8th February 2018

From: Marketing

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
KVA

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...